Important Information from Clinical Trials on Hepatitis C Virus

Very important data from Boehringer Ingelheim's hepatitis C virus clinical trial programme, HCVersoTM, specializing in interferon-free therapy is selected for incorporation within the official European Association for Study of the Liver press office activities. Each of these data are certainly one of five abstracts from varieties of new Boehringer Ingelheim HCV data, which have been recognized for identification for the International Liver Congress (ILC)TM 2012, happening 18th - 22nd April in Barcelona in Spain.

Boehringer Ingelheim's recognized abstracts not included in EASL media actions might be accessed from the EASL website, www.easl.eu. The Boehringer Ingelheim facts present in EASL media actions should stay under embargo till the time of display on 21st April. All Boehringer Ingelheim's data displays are listed below.

Mutually, each of these data underscores the organizations focus on finding solutions towards the challenges faced by HCV patients.

Boehringer Ingelheim is continuous to aid its aim of delivering an easier HCV cure for many affected individuals, such as those toughest as a treatment for through the organization's rigorous clinical trial programme, HCVersoTM.